April 17 (Reuters) - The U.S. Food and Drug Administration has approved Gamida Cell Ltd's blood cancer therapy, Omisirge, the health regulator said on Monday. (Reporting by Pratik Jain in Bengaluru)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 USD | +2.41% | -.--% | -95.88% |
May. 23 | Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 10 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-95.88% | 2.62M | |
+14.09% | 118B | |
+13.62% | 106B | |
-2.04% | 24.28B | |
+0.79% | 21.96B | |
-9.21% | 18.16B | |
-42.12% | 16.37B | |
-17.30% | 15.56B | |
+5.82% | 13.63B | |
+30.35% | 12.27B |
- Stock Market
- Equities
- GMDA Stock
- News Gamida Cell Ltd.
- US FDA approves Gamida's blood cancer therapy